ProMIS Neurosciences Reports Positive Interim Data for Alzheimer’s Drug PMN310 — ProMIS Neurosciences Inc.

Event summary

ProMIS Neurosciences reported positive blinded six-month interim safety and biomarker results from its Phase 1b trial (PRECISE-AD) of PMN310 in early Alzheimer’s patients, with zero cases of ARIA-E across all participants.
The company ended Q2 2026 with $53.4 million in cash and short-term investments, sufficient to fund operations through 2027.
PRECISE-AD trial observed early declines in plasma pTau217 (15%) and CSF MTBR-tau243 (13.3%) biomarkers in a blinded analysis.
PMN310 is designed to selectively target toxic amyloid-beta oligomers, potentially reducing ARIA liability compared to plaque-binding antibodies.

The big picture

ProMIS Neurosciences’ interim data suggests a potential breakthrough in Alzheimer’s treatment by targeting toxic amyloid-beta oligomers without the ARIA risks associated with plaque-binding antibodies. The company’s strong cash position provides runway to critical milestones, but success hinges on confirming these early signals in unblinded results. The broader biotech sector is watching closely as selective targeting of misfolded proteins could redefine therapeutic approaches for neurodegenerative diseases.

What we're watching

Clinical Efficacy: Whether the unblinded 12-month topline data from PRECISE-AD, expected in Q1 2027, will confirm the early biomarker trends and demonstrate cognitive benefits.
Regulatory Pathway: How the differentiated safety profile of PMN310 may influence regulatory discussions and potential Fast Track designation.
Pipeline Progress: The pace at which ProMIS advances its other programs, including PMN267 for ALS/FTD and PMN442 for Parkinson’s disease, toward IND-enabling studies.